Best of ASCO - 2014 Annual Meeting

 

Welcome

Metastatic Non-Small Cell Lung Cancer

Lung Cancer—Non-Small Cell Metastatic

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
Association of STK11/LKB1 mutations with primary resistance to PD-1/PD-L1 axis blockade in PD-L1 positive non-squamous NSCLC.

Ferdinandos Skoulidis

9028

RET-rearranged lung cancers: Immunophenotype and response to immunotherapy.

Joshua K. Sabari

9034

24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC.

Ryan D. Gentzler

9026

4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.

Enriqueta Felip

9030

A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer.

Mark A. Socinski

109

A comparative study of ALK and ROS genes rearrangements among IHC/FISH/CLART in NSCLC.

Maria Cortes-Sempere

e21152

A comparison of three clinical factors as predictive markers for response to immunotherapy in non-small cell lung cancer.

Isabel Ruth Preeshagul

e21158

A multicenter observational study of effectiveness and safety of nivolumab in non-small cell lung cancer in real clinical practice.

Juan Francisco Marín Pozo

e21092

A multicenter phase II study of low-dose erlotinib in frail patients with EGFR mutation-positive, non-small cell lung cancer: Thoracic oncology research group (TORG) trial 1425.

Kazuhiko Yamada

9063

A multicenter, randomized, double-blind, placebo-controlled phase III study of apatinib or placebo plus gefitinib as first-line treatment in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC).

Hongyun Zhao

TPS9116

A new algorithm predicting imminent disease progression in advanced NSCLC patients by machine-learning integration of five serum biomarkers.

Yuri Kogan

e21190

A phase 1/2 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated non-squamous NSCLC.

Sawsan Rashdan

e21043

A phase 1b trial of RORγ agonist LYC-55716 in combination with pembrolizumab to evaluate safety, efficacy, and immune biomarker profiles in patients with metastatic non-small cell lung cancer.

D. Ross Camidge

TPS9111

A phase 2 study of poziotinib in patients with EGFR or HER2 exon 20 mutation-positive non-small cell lung cancer.

Zandong Yang

TPS9106

A phase Ib study of SHR-1210 plus apatinib for heavily previously treated advanced non-squamous non-small cell lung cancer (NSCLC) patients.

Caicun Zhou

e21017

A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor (TKI) naïve patients with advanced NSCLC.

Aaron Elliott Lisberg

9014

A phase II trial of albumin-bound paclitaxel and gemcitabine in patients with newly diagnosed PD-L1 IHC low/unknown stage IV squamous cell lung cancers.

Paul K. Paik

e21035

A pilot trial assessing apatinib combined with docetaxel (DTX) as second-line chemotherapy for EGFR negative advanced non-small-cell lung cancer (NSCLC).

Yong Song

e21113

A randomized phase 2 study of abemaciclib versus docetaxel in patients with stage IV squamous non-small cell lung cancer (sqNSCLC) previously treated with platinum-based chemotherapy.

Giorgio V. Scagliotti

9059

A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.

Jonathan Wade Goldman

9025

A randomized phase II trial of maintenance oral metronomic vinorelbine versus close observation in advanced non-small cell lung cancer (NSCLC) following platinum-based chemotherapy: MA.NI.LA. trial.

Marco Platania

e21101

A real-world survival of subsequent therapy in ALK positive non-small cell lung cancer (NSCLC) patients with crizotinib resistance.

Lu Yang

e21093

A retrospective analysis of the efficacy of immune checkpoint inhibitors (ICIs) to advanced non-small cell cancer (NSCLC) patients (pts) with central nerve system (CNS) metastasis.

Takashi Sone

e21042

A trial of CV301 in combination with anti-PD-1 therapy versus anti-PD-1 therapy in subjects with non-small cell lung cancer.

Arun Rajan

TPS9108

Afatinib in combination with pembrolizumab in patients (pts) with stage IIIB/IV squamous cell carcinoma (SCC) of the lung.

Benjamin Philip Levy

TPS9117

An amplicon-based liquid biopsy for detecting ALK and ROS1 fusions and resistance mutations in advanced non-small cell lung cancer (NSCLC) patients.

Laura Mezquita

9095

An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer.

Alexander Liede

e21001

An open-label, multicenter, phase II single arm trial of osimertinib in non-small cell lung cancer patients with uncommon EGFR mutation (KCSG-LU15-09).

Myung-Ju Ahn

9050

Anaplastic lymphoma kinase (ALK) positive tumors: Clinical, radiographic and genomic characteristics, and unusual sites of metastases.

Rohan Gupta

e21130

Apatinib plus S-1 as second-line or laterline chemotherapy for advanced squamous cell lung carcinoma.

Qingming Shi

e21179

Application of a cancer hot-spot panel to guide lung cancer therapy: Asian experience.

Yi-Ting Yang

e21189

Assessing the uncertainty around the survival estimates used in multi-criteria decision anlaysis (MCDA). the alectinib case in Argentina using the Latin America federation of pharmaceutical industry (FIFARMA) framework.

Panos Orfanos

e21123

Association between efficacy of immunotherapy and rate of cancer progression at the time of initiation of immunotherapy: An analysis in metastatic non-small cell lung cancer (NSCLC).

Thiru Prasanna

e21225

Association between ERCC1 polymorphisms and nephrotoxicity in non-small cell lung cancer patients undergoing platinum-based chemotherapy.

Corine de Jong

e21177

Association of baseline and longitudinal low neutrophil-lymphocyte ratio (NLR) and high lymphocyte counts (LCs) with progression-free survival (PFS) and overall survival (OS) in real world advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with nivolumab (nivo) or pembrolizumab (pembro).

Stephanie Labomascus

e21020

Association of CDKN2A gene alteration with high expression of PD-L1.

Yan Zhang

9102

Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer.

Marcelo Vailati Negrao

9052

Association of pre-existing thyroid autoimmunity with the development of thyroid dysfunction induced by nivolumab.

Shiro Kimbara

9091

Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101.

Alice Tsang Shaw

9008

Avelumab (anti–PD-L1) in patients with platinum-treated advanced NSCLC: 2.5-year follow-up from the JAVELIN Solid Tumor trial.

Arun Rajan

9090

Body composition as predictor of toxicity and outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) receiving nivolumab (Nivo).

Shlomit Strulov Shachar

e21010

BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: Results from a first-in-human, phase I, dose-escalation study.

Xingsheng Hu

e21108

BRAF-mutant non-small cell lung cancer (NSCLC): Patient (pt) characteristics and outcomes by class of mutation.

Ibiayi Dagogo-Jack

9045

Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non–small cell lung cancer (NSCLC): Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status.

Rudolf M. Huber

9061

Can duration of response be used as a surrogate endpoint for overall survival in advanced non-small cell lung cancer?

Boris M Pfeiffer

9082

Can nutritional status predict survival in patients with advanced non-small cell lung cancer?

Sookyung Lee

e21096

Characteristics of K-ras mutation lung cancer in an East Asian institute.

Passakorn Wanchaijiraboon

e21206

Characterization of 1,233 NSCLCs with non-del19/L858R EGFR mutations (EGFRm) using comprehensive genomic profiling (CGP).

Sai-Hong Ignatius Ou

9040

Circulating free DNA (cfDNA) for personalized treatment of lung cancer patients without cytopathologic diagnosis.

Aditi Puri Singh

e21143

Circulating tumor DNA in advanced lung cancers: A prospective evaluation of matched therapy and shedding detection.

Michael David Offin

e21234

Clinical activity of afatinib in a cohort of patients with lung adenocarcinoma harbouring uncommon EGFR mutations: A Spanish retrospective multicentre study.

Manuel Domine

e21028

Clinical and molecular features predicting long-term response (LTR) to anti-PD-(L)1 based therapy in patients with NSCLC.

Hira Rizvi

9022

Clinical characterization and in silico drug sensitivity prediction model of rare EGFR mutations in non-small cell lung cancer.

Shinnosuke Ikemura

e21221

Clinical concordance study of a 17-gene liquid biopsy NGS panel for non-small cell lung cancer (NSCLC).

Lee Steven Schwartzberg

e21065

Clinical efficacy and safety of apatinib combined with EGFR-TKIs in advanced non-small cell lung cancer with EGFR-TKIs resistance.

Ruifen Tian

e21172

Clinical outcomes of African-American patients with advanced or metastatic non-small cell lung cancer on nivolumab in a single community based cancer center.

Andrew Chua Tiu

e21131

Clinical outcomes of EGFR exon 20 insertion in advanced NSCLC in Korea.

Seonggyu Byeon

e21136

Clinical outcomes of patients with lung cancer treated with radiotherapy and ANTI-PD-1 therapy: A multicenter retrospective analysis from GFPC Group.

Delphine Lerouge

e21077

Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer.

Motohiro Tamiya

e21155

Clinical utility of cfDNA analysis in advanced stage NSCLC and other solid tumors in patients from Colombia.

Silvia Juliana Maradei

e21205

Clinical utility of plasma-based digital next-generation sequencing (NGS) in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.

Jon Zugazagoitia

9101

Clinical, pathological and molecular characterization of long-term survivors with advanced non-small cell lung cancer: A multicenter experience in Madrid.

Maria Sereno

e21128

Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A randomized phase 2 study (GOAL, Spanish Lung Cancer Group).

Rosario Garcia Campelo

9012

Combination of metformin plus TKI vs. TKI alone in EGFR(+) LUNG adenocarcinoma: A randomized phase II study.

Oscar Gerardo Arrieta Rodriguez

9013

Combined treatment of apatinib with docetaxel as post second-line therapy in advanced non-squamous non-small cell lung cancer(NSCLC): Results from a pilot, multi-center study.

Daiyuan Ma

e21213

Comparative effectiveness of carboplatin-pemetrexed (Carbo-Pem) with vs. without bevacizumab (Bev) in patients with advanced non-squamous (Sq) non-small cell lung cancer (NSCLC).

Stephen Joseph Bagley

9073

Comparative effectiveness study of first-line pemetrexed-platinum doublet chemotherapy with or without bevacizumab for Chinese patients with advanced non-squamous non-small-cell lung cancer.

Xiaoyou Li

e21053

Comparative efficacy and safety of immunotherapies targeting PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: Bayesian network meta-analysis.

Abdulaali Almutairi

e21012

Comparison of immunotherapy response rates in non-small cell lung cancer following platinum-based chemotherapy.

Taylor Mai Weis

e21175

Comparison of outcomes with PD-L1 tumor proportion score (TPS) of 50-74% vs 75-100% in patients with non-small cell lung cancer (NSCLC) treated with first-line PD-1 inhibitors.

Elizabeth Jimenez Aguilar

9037

Comprehensive circulating tumor DNA profiling of driver genes in Chinese NSCLC patients.

Jianji Guo

e21144

Comprehensive genomic profiling of lung cancer cytologic specimens obtained by guided fine-needle aspirate biopsies.

Sugganth Daniel

e21002

Comprehensive mutation profiling and treatment choices of 111 Chinese advanced lung cancer patients in the real world setting.

Xiaorong Dong

e21201

Concurrent genomic alterations in lung adenocarcinoma with a MET exon 14 skipping mutation.

Julia Rotow

9083

Contribution of nationwide genome screening in Japan (LC-SCRUM-Japan) to the development of precision medicine for non-small cell lung cancer.

Takashi Seto

9085

Correlation between nivolumab exposure and treatment outcome in NSCLC.

Stijn L.W. Koolen

9057

Correlation between the TTF-1 expression and immune-related thyroid dysfunction and efficacy of anti-PD1 treatment in non-small cell lung cancer.

Junji Koyama

e21100

Correlation of PBMC CD62Llow CD4+ T cells with irILD after nivolumab therapy.

Ou Yamaguchi

e21018

Correlation of survival of NSCLC patients given nivolumab with treatment related-eosinophilia, autoimmunity and previous bevacizumab containing regimens.

Rocco Giannicola

e21008

C-reactive protein (CRP) as a predictive marker for survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first line pembrolizumab monotherapy.

Yuji Shibata

e21106

Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.

D. Ross Camidge

9062

Crizotinib with bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer harboring EML4-ALK fusion variant mutation: A prospective exploratory study.

Bo Yang

e21186

CT perfusion in patients with advanced lung adenocarcinoma treated with conventional chemotherapy and antiangiogenesis therapy.

Ling-yu Ding

e21099

Dacomitinib (daco) versus gefitinib (gef) for first-line treatment of advanced NSCLC (ARCHER 1050): Final overall survival (OS) analysis.

Tony Mok

9004

Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC.

Kathryn Cecilia Arbour

9003

Demographic composition of lung cancer trials: FDA analysis.

Lola A. Fashoyin-Aje

9088

Dendritic-cell vaccine (DCVAC) with first line chemotherapy in patients with stage IV NSCLC primary analysis of phase 2, open-label, randomized, multicenter trial.

Libor Havel

9051

Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292.

Geoffrey R. Oxnard

9048

Detection of EGFR mutations in cfDNA and development of resistance.

Grainne M. O'Kane

e21072

Development of genetic profiles-based nomograms for predicting survival among EGFR-mutant lung cancer.

Rui-lian Chen

e21219

Differences between epidermal growth factor receptor mutation status and clinic and radiologic features in metastatic lung adenocancer pati̇ents treated with erlotinib.

Metin Ozkan

e21217

Different degree of response to checkpoint inhibitors in metastatic NSCLC patients according to mutations within KRAS gene.

Alfredo Addeo

e21061

Differential outcomes in patients with uncommon EGFR exon 19 mutations.

Tyler Stewart

9056

Disadvantaged subgroups of metastatic non-small cell lung cancer (mNSCLC) patients treated with nivolumab.

Sabrina Rossi

e21116

Dissecting the prognostic role of common EGFR-mutations of metastatic NSCLC in TKI era: A systematic review and subgroup meta-analysis.

Feng-Che Kuan

9079

Dose expansion cohort of a phase I trial of M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC).

Elizabeth Ruth Plummer

e21048

Durvalumab in ≥ 3rd-line advanced NSCLC: Updated results from the phase 2 ATLANTIC study.

Marina Chiara Garassino

9058

Dynamic monitoring and predictive value of circulating tumor cells in EGFR mutant advanced NSCLC patients treated with first-line EGFR-TKIs.

ChunXia Su

e21045

Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial.

Frances A. Shepherd

9027

Early determination of benefit or futility in treating NSCLC using the LCSS 3-Item Global Index (3-IGI).

Richard J. Gralla

9086

Early prediction of outcomes to PD1 inhibitors in non-small cell lung cancer (NSCLC) using next generation sequencing (NGS) of plasma circulating tumor DNA (ctDNA).

Nicolas Guibert

9078

ECHO-305/KEYNOTE-654: A phase 3, randomized, double-blind study of first-line epacadostat plus pembrolizumab vs pembrolizumab plus placebo for metastatic non–small cell lung cancer (mNSCLC) with high PD-L1 levels.

Mark M. Awad

TPS9109

ECHO-306/KEYNOTE-715: A phase 3 study of first-line epacadostat plus pembrolizumab with or without platinum-based chemotherapy vs pembrolizumab plus platinum-based chemotherapy plus placebo for metastatic non–small cell lung cancer (mNSCLC).

Rina Hui

TPS9104

Economic evaluation of diagnostic platforms for T790M detection in post EGFR-TKI NSCLC in Brazil.

Carlos G. M. Ferreira

e21159

Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model.

Nathan A. Pennell

9031

Effect of EGFR C797S/G mutation on osimertinib resistance in Chinese patients with non-small-cell lung cancer.

Keke Nie

e21171

Effect of PDL1 expression [exp] on overall survival [OS] in patients [pts] with metastatic adenocarcinoma lung [MAC]: Illinois CancerCare [ILCC] analysis.

Allison Frey

e21125

Effectiveness of icotinib against non–small-cell lung cancer with uncommon EGFR mutations.

Shengyu Zhou

e21083

Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy.

Leena Gandhi

9036

Efficacy and safety of low-dosage apatinib monotherapy in advanced lung squamous cell carcinoma.

Qian Geng

e21170

Efficacy and safety results of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant NSCLC.

David Planchard

9053

Efficacy and tolerance of immune-checkpoint inhibitors in EGR, ALK/ROS 1 non-small-cell-lung-cancer (NSCLC): GFPC 03-2016 IMAD study.

Olivier Bylicki

e21022

Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).

Julien Mazieres

9010

Efficacy of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim results of observational prospective study.

Konstantin K. Laktionov

e21126

Efficacy of weekly vinorelbine monotherapy in patients with lung adenocarcinoma.

Da Hyun Kang

e21157

Efficiency of anlotinib hydrochloride as 3rd line treatment in patients (pts) from a randomized, double-blind, placebo-controlled phase III trial, an exploratory subgroup analysis of ALTER0303 trial for the previous therapy strategy effect.

Qiming Wang

e21182

EGFR and ERBB2 to determine the metastatic status of mediastinal lymph nodes in lung adenocarcinomas harbouring EGFR mutation.

Wanning Yang

e21215

EGFR reporting in stage IV adenocarcinoma of the lung: Demographic predictors of EGFR testing and survival.

Shagufta Shaheen

9100

Ensartinib (X-396), a second-generation ALK TKI, in Chinese ALK-positive non-small cell lung cancer: A phase I, dose-escalation study.

Wenfeng Fang

e21122

Epidermal growth factor receptor (EGFR) exon 20 mutations in EGFR-tyrosine kinase inhibitors (EGFR-TKIs) naive non-small cell lung carcinoma (NSCLC) and response to erlotinib therapy.

Adnan Aydiner

e21212

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) impact on immune microenvironment in non-small cell lung cancer (NSCLC).

Jie Tang

e21154

Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): Survival follow-up results of JO25567.

Noboru Yamamoto

9007

Evaluating and treating lesser-income patients with lung cancer in south asia: Where are the delays?

Vishal Vashistha

e21094

Evaluation of EGFR diagnostic testing and treatment patterns in advanced NSCLC patients over time.

Victor C Wang

e21030

Evaluation of liquid biopsies for molecular profiling in patients (pts) with advanced non-small cell lung cancer (NSCLC): What happens after panel testing by next generation sequencing (NGS)?

Jing Zhao

e21210

eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients.

Leora Horn

TPS9115

Exome analysis to reveal genomic markers associated with better efficacy of nivolumab in lung cancer patients.

Corentin Richard

9044

Experience of nivolumab and pembrolizumab in metastatic non-small cell lung cancer in routine clinical practice (mNSCLC.).

Doran Ksienski

e21227

Exposure-response (ER) analysis of alectinib (ALC) in crizotinib-resistant ALK-positive non-small cell lung cancer (NSCLC).

Peter N. Morcos

e21137

Feasibility of continuing crizotinib therapy after RECIST-PD in advanced non-small cell lung cancer patients with ALK/ROS-1 mutations.

Jun Liu

e21132

Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma.

Allison M. Campbell

9099

First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP.

Vassiliki Papadimitrakopoulou

9019

First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non–small cell lung cancer (NSCLC).

Robert Charles Doebele

9015

Frequency of brain metastases and outcomes in patients with HER2-, KRAS-, and EGFR-mutant lung cancers.

Mark G. Kris

9081

Fusion detection and longitudinal circulating tumor DNA (ctDNA) profiling in ALK+ non-small cell lung cancer (NSCLC) patients.

Aurélie Swalduz

e21031

Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery and intravenous infusion.

Abeer F Alharbi

e21195

Gemcitabine-cisplatin (GC) + necitumumab (N) versus GC as first-line treatment for stage IV squamous cell lung cancer (SqCLC): An open-label randomized multicenter phase Ib-II trial in Japan.

Hiroshige Yoshioka

9038

Genetic aberrations related to increased risks of brain metastasis in non-small cell lung cancer (GASTO-1036).

Delan Li

9092

Health-related quality of life (HRQoL) in the KEYNOTE-189 study of pembrolizumab (pembro) or placebo (pbo) + pemetrexed (pem) + platinum (plt) for metastatic NSCLC.

Marina Chiara Garassino

9021

High incident of EGFR mutant for lung cancer brain metastases patients and low risk of brain metastases in hippocampus.

Xingwen Fan

e21200

High prevalence of anemia in newly diagnosed lung cancer patients undergoing chemotherapy: Associations and prognostic value.

Navneet Singh

e21169

Hospitalizations and emergency department (ED) visits pre- and post-approval of immuno-oncology agents (IO) in advanced non-small cell lung cancer (aNSCLC).

Janna Radtchenko

e21006

How to manage ctDNA monitoring with EGFR inhibitors?

Jerome Solassol

e21202

Hyperprogression after immunotherapy: Clinical implication and genomic alterations in advanced non-small cell lung cancer patients (NSCLC).

Youjin Kim

9075

Identification of leptomeningeal metastasis-specific exosomal miRNA signature in cerebrospinal fluid of non-small-cell lung cancer patients.

Ben-Yuan Jiang

e21024

Identification of osimertinib resistance mechanisms in Chinese NSCLC patients: Analysis from AURA17 trial.

Min Hu

9077

Identification of osimertinib resistance mechanisms using plasma cell-free DNA and tissue biopsy in EGFR-mutated T790M-positive Japanese patients with lung cancer.

Ryo Ariyasu

e21051

Identifying t cell profiles that associate with clinical response to anti-PD-1 treatment in non-small cell lung carcinoma (NSCLC) patients.

Andre Kunert

e21239

Immune checkpoint inhibitor efficacy and safety in elderly non-small cell lung cancer patients.

Hiromi Watanabe

e21034

Immune-related adverse events and nivolumab outcomes in non-small cell lung cancer patients: A multi-institutional, retrospective cohort study.

Rebecca Jane Moor

9067

Immune-related adverse events to predict survival in patients with advanced non-small cell lung cancer treated with nivolumab: A multicenter analysis.

Biagio Ricciuti

9084

Immuno-oncology biomarker study in a large cohort of LC-SCRUM-Japan: Assessment of PD-L1 expression and tumor mutation burden in non-small cell lung cancer patients treated with immune checkpoint inhibitors.

Kiyotaka Yoh

9070

Immunotherapy (I) for advanced, pre-treated, non-squamous NSCLC (APNS-NSCLC): Preliminary data of a pooled analysis.

Ilaria Morriconi

e21032

Immunotherapy for advanced non-small cell lung cancer (NSCLC): Experience at Louis Stokes Cleveland VA Medical Center (LSCVAMC).

Paige Sinclair

e21148

Impact of central nervous system (CNS) involvement in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with immune checkpoint inhibitors (ICI).

Lizza Hendriks

9066

Impact of clinical stage at diagnosis on outcomes with nivolumab in patients with lung cancer.

Surabhi Pathak

e21104

Impact of TP53 mutations on efficacy of PD-1 targeted immunotherapy in non-small cell lung cancer (NSCLC).

Jennifer Wilkinson Carlisle

e21090

Impact of tyrosine kinase inhibitor (TKI) dose on outcomes of patients with lung cancer.

Emily Miao

e21081

Implementation of a democratized approach to multi-omic molecular profiling via the LungMATCH program.

Jennifer C. King

e21033

IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

Robert M. Jotte

LBA9000

Improvement of NGS uniformity of single cell sequencing in CTCs by WGA QC and increased sequencing throughput.

Lin Ze Shiang

e21176

Increase in tumor burden at disease progression as a predictor of survival in advanced NSCLC patients.

Yuri Kogan

e21114

Inflammatory biomarkers for prediction of tumor responses and adverse events in non-small cell lung cancer patients treated with anti-PD-1 inhibitor.

Norikazu Matsuo

e21050

Inflammatory biomarkers in HIV-infected veterans with non-small cell lung cancer receiving anti–PD-1 immunotherapy.

Elaine Chang

e21110

Initial tumor flare or mixed tumor response following single PD-1 vs. dual PD-1/CTLA-4 blockade in non-small cell lung cancer (NSCLC).

Monica Sheila Chatwal

e21037

Insurance disparity and outcomes among younger non-small cell lung cancer (NSCLC) patients: A SEER analysis 2007-2014.

Qian Wang

e21049

Landscape of EGFR-dependent and independent mechanisms of osimertinib resistance in EGFR-mutant NSCLC patients.

Xiuning Le

9087

Leptomeningeal metastases after the effective first-generation EGFR TKI treatment in advanced non-small cell lung cancer.

Yong-Mei Liu

e21059

Liquid thermal biopsy as a new non-invasive method of diagnosis for lung cancer patients.

Alberto Rodrigo

e21207

Local ablative therapy (LAT) for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib.

Chul Kim

e21080

Long term effect of nivolumab in patients with non-small cell lung cancer.

Mette Sprauten

e21156

Long-term efficacy and outcomes with sequential crizotinib followed by alectinib in ALK+ NSCLC.

Jessica Jiyeong Lin

9093

Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety.

Benjamin Besse

9032

Lower prevalence of PD-L1 expression in advanced non-small lung cancer in Brazil.

Ana Caroline Gelatti

e21140

Lung cancer liquid biopsy assays by qPCR using iDDS probe and Wild Terminator methods.

Zhonglin Hao

e21178

Management of patients with advanced NSCLC without actionable mutations: A simulation-based assessment of medical oncologists.

Tara Herrmann

e21041

Mature progression-free survival (PFS) milestones in real world stage IV, non-squamous, non-small cell lung cancer patients (nsqNSCLC) treated with first line pemetrexed(Pem)/platinum(Plat) +/- bevacizumab(Bev) followed by pem +/-bev maintenance.

Parva Kiran Bhatt

e21063

Mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKIs) in MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC).

Mark M. Awad

9069

Meta-analysis exploring the effect of oncogenic driver mutations on outcome of metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICI) or docetaxel (doc).

Abena Agyeman

9029

Modulation of autophagy with hydroxychloroquine in patients with advanced non-small cell lung cancer (NSCLC): A phase Ib study.

Jyoti Malhotra

e21138

Molecular predictors of long-term response to crizotinib in ALK+ advanced non-small cell lung cancer (NSCLC) patients.

Mathilde Couetoux du Tertre

e21038

Molecular testing in advanced non-squamous NSCLC in a community setting.

James J. Kim

e21204

Molecular testing, frequency of molecular alterations and targeted 1st-line treatment of patients with non-small cell lung carcinoma in Germany: First results from the prospective German Registry CRISP (AIO-TRK-0315).

Frank Griesinger

e21236

Monocytes and neutrophils as a predictive marker of response to immune checkpoint inhibitors (ICI) in metastatic non-small cell lung cancer (mNSCLC).

Kaushal Parikh

e21165

MORPHEUS: A phase Ib/II multi-trial platform evaluating the safety and efficacy of cancer immunotherapy (CIT)-based combinations in patients (pts) with non-small cell lung cancer (NSCLC).

Melissa Lynne Johnson

TPS9105

Multicenter study for the correlation among PD-L1 antibodies, tumor mutation burden (TMB) and lung immune prognostic index (lipi) in Chinese patients with advanced lung adenocarcinoma.

Jianming Ying

e21218

Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer.

Vivek Subbiah

9035

Mutation profiling and treatment choosing of Chinese ROS1 positive advanced lung cancer patients.

Jun Zhao

e21102

Mutation profiling and treatment choosing of Chinese RET positive advanced lung cancer patients.

Jun Zhao

e21139

Neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) as predictive indicators of nivolumab efficacy in metastatic non-small cell lung cancer (mNSCLC).

Sabrina Rossi

e21115

Next generation sequencing (NGS) based mutation profiling and heterogeneity of resistance mechanisms to AZD9291.

Jun Zhao

9068

Nivolumab (Nivo) + Ipilimumab (Ipi) vs Platinum-Doublet Chemotherapy (Chemo) as First-line (1L) Treatment (Tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Safety Analysis and Patient-Reported Outcomes (PROs) From CheckMate 227.

Martin Reck

9020

Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227.

Hossein Borghaei

9001

Non-invasive analysis of three disease-progression modes in NSCLC patients after taking EGFR-TKIs by next-generation sequencing.

Yuqing Wei

e21168

Novel antiangiogenic drugs, immune checkpoint inhibitors, and chemotherapy in patients with aNSCLC who have aggressive disease: A systematic review.

Katherine B. Winfree

e21120

OS outcomes to anlotinib in patients (pts) with refractory NSCLC of both wild-type (WT) and mutant EGFR.

Kai Li

e21013

Outcomes of immunomodulatory radiation strategies in combination with nivolumab compared with single agent nivolumab in lung cancer patients.

Aparna Madhukeshwar Hegde

e21134

Outcomes with chemotherapy for metastatic non-small cell lung cancer (mNSCLC) in patients previously treated with immune checkpoint inhibitors (CPI).

Radowan Elnair

e21119

Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.

Mark A. Socinski

9002

Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC).

Martin Reck

9047

Patterns of care in long term survivors (>3 years) in metastatic NSCLC : A subset analysis of 30 patients from a single institute.

Y Indibor Singh

e21185

PD-L1 expression, tumor mutation burden and response to immune checkpoint blockade in patients with HER2-mutant lung cancers.

Wei-Chu Victoria Lai

9060

Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.

Gilberto Lopes

LBA4

PET scan metabolic activity and programmed cell death-ligand 1 expression in lung cancer patients: Is there a correlation?

Heather Katz

e21199

Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC.

Pasi A. Janne

TPS9110

Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC).

Leena Gandhi

TPS9107

Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).

Luis G. Paz-Ares

105

Phase I study of apatinib combined with docetaxel in EGFR-negative advanced non-small cell lung cancer (NSCLC).

Jianchun Duan

e21184

Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).

Andreas Nicholas Saltos

9046

Phase I/II study of nivolumab and ipilimumab combined with nintedanib in advanced NSCLC.

Sonam Puri

TPS9112

Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC.

Alberto Chiappori

9089

Phase I/II trial of dasatinib and osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer.

Chul Kim

TPS9113

Phase II trial of carboplatin and pemetrexed plus bevacizumab with maintenance bevacizumab as first-line treatment for elderly patients with advanced non-squamous non-small cell lung cancer.

Hiroaki Takeoka

e21180

Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026.

Naoki Furuya

9006

Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009).

Atsushi Nakamura

9005

Pneumonitis in advanced non-small-cell lung cancer (NSCLC) patients (pts) treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI): Meta-analysis of 153 trial cohorts with 15,713 pts.

Chong Hyun Suh

e21223

Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC).

Sai-Hong Ignatius Ou

9072

Population pharmacokinetics (PopPK) and exposure-response (ER) analyses to confirm the global alectinib (ALC) 600mg BID dose in the Chinese treatment-naïve population.

Joy Hsu

e21133

Post- progression treatment patterns in advanced lung cancer patients treated with nivolumab.

Aparna Madhukeshwar Hegde

e21070

Potential challenge for second-line treatments of unresectable locally or advanced-stage non-small-cell lung carcinoma unharbored sensitive driver gene mutation: A pilot study of novel antiangiogenesis inhibitor (NCT: 0325672121).

Zongyang Yu

e21197

Potential role of serial liquid biopsies to guide treatment decisions in NSCLC.

Todd Cory Knepper

e21079

Predictive biomarkers of response to anti-PD-1 treatment in non-small cell lung cancer patients.

Xuan Zheng

e21076

Predictive value of CD73 expression in EGFR-mutation positive non-small-cell lung cancer patients received immune checkpoint inhibitors.

Hidenobu Ishii

9065

Predictors of clinical benefit of checkpoint inhibitors-based immunotherapy in advanced non–small cell lung cancer: A meta-analysis.

Hazem Edmond El-Osta

e21121

Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC).

Dong-Wan Kim

9094

Prevalence [P] of molecular biomarkers [MB] expression [exp] in patients [pts] with metastatic adenocarcinoma lung [MAC]: Illinois CancerCare [ILCC] analysis.

Pankaj Kumar

e21124

Prevalence and prognosis of DNA repair deficiency in squamous cell carcinoma (SCC) patients enrolled on the S1400 LungMAP study.

Taofeek Kunle Owonikoko

9055

Profiling and treatment patterns in NSCLC patients with CNS (brain) metastases in Europe and Asia.

Ettore Mari

e21085

Prognosis of lung cancer as a second primary malignancy among cancer survivors: A population-based cohort study.

Lei Deng

e21005

Prognosis of thoracic radiation-induced metastatic NSCLC.

Marie Florescu

e21095

Prognostic factors in oligometastatic non-small-cell lung cancer (OM-NSCLC) patients treated with ablative therapy.

Juan Antonio Mendez

e21089

Prognostic impact of KRAS mutation subtype and concurrent genetic mutations in non-small cell lung cancer.

Jacqueline Aredo

e21023

Prognostic relevance of tumor sequencing in metastatic lung adenocarcinomas.

Ronglai Shen

9049

Prognostic value of neutrophil-to-lymphocyte ratio (NLR), serum albumin and sequence of immunotherapy (Immuno.) on overall survival (OS), and progression free survival (PFS) in patients with metastatic non-small cell lung cancer (NSCLC) treated with ramucirumab plus docetaxel (RD).

Ibtihaj Fughhi

e21163

Programmed death-ligand 1 expression after progressive disease with EGFR-TKI and efficacy of anti-programmed death-1 antibody in non-small cell lung cancer(NSCLC) harboring EGFR mutation.

Yosuke Dotsu

e21232

Progression-free survival as surrogate endpoint for overall survival in NSCLC trials of anti PD-1 and anti PD-L1 agents and the impact of line of treatment.

Anandaroop Dasgupta

e21135

Quality of life analysis of Pemetrexed versus Erlotinib maintenance in EGFR mutation negative advanced non small cell lung cancer.

Vivek Agarwala

9024

Quantification of the independent prognostic value of Charlson Comorbidity Index among patients with non-small cell lung cancer.

Jianfeng Meng

e21164

Quantitative CT texture assessment of tumour heterogeneity to predict those patients with non-small cell lung cancer most likely to benefit from immune checkpoint inhibitors.

Rahul Ladwa

e21027

Radium-223 following front-line chemotherapy for patients with non-small cell lung cancer and bone metastases.

Angela Marie Taber

e21211

Ramucirumab (ram), immune checkpoint inhibitors (ICIs), and single-agent chemotherapy (chemo) usage in real-world advanced non-small cell lung cancer (aNSCLC) patients (pts) after rapid disease progression (RDP) on platinum (Pt).

Marta Batus

e21162

Randomized phase II study of pembrolizumab after stereotactic body radiotherapy (SBRT) versus pembrolizumab alone in patients with advanced non-small cell lung cancer: The PEMBRO-RT study.

Willemijn Theelen

9023

Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.

Julien Mazieres

9097

Randomized phase II trial of oral vinorelbine (OV) and cisplatin (P) followed by maintenance with single-agent OV versus (vs) gemcitabine (GEM) and P followed by maintenance with single-agent GEM as first-line chemotherapy (CT) in locally advanced (LA) or metastatic non-small-cell lung cancer (NSCLC) patients (pts) with squamous (sq) histological type.

Francesco Grossi

e21058

Rapid drop in blood platelet count and increase in creatinine in non-small cell lung cancer (NSCLC) patients treated with osimertinib.

Inger Johanne Zwicky Eide

e21026

Rare targetable drivers (RTD) in NSCLC: PD-L1 expression, tumor mutation burden (TMB), microsatellite instability (MSI) and outcomes with immune check-point inhibitors (ICPi).

Elizabeth Dudnik

9076

Real world experience with pembrolizumab and nivolumab for treatment of non-small cell lung cancer (NSCLC) in an Irish Regional Cancer Center.

Colum Dennehy

e21196

Real world study of afatinib in first-line or re-challenge setting for patients with EGFR mutant non-small cell lung cancer.

Hisashi Tanaka

e21173

Real-world clinical characteristics and treatment of advanced non-small cell lung cancer (NSCLC) patients in China.

Yuankai Shi

e21187

Real-world dose adjustment study of first-line afatinib in pts with EGFR mutation-positive (EGFRm+) advanced NSCLC.

Balazs Halmos

e21060

Real-world treatment patterns and survival of BRAF V600-mutated metastatic non-small cell lung cancer patients.

Leora Horn

9096

Rebiopsy status among non-small cell lung cancer patients after Icotinib therapy in China.

Hanping Wang

e21146

Refining the sensitivity of plasma cell-free DNA (cfDNA) genotyping by controlling for plasma tumor content.

Catherine Meador

9071

Response and durability of anti-PD-(L)1 therapy in never- or light-smokers with non-small cell lung cancer (NSCLC) and high PD-L1 expression.

Justin F. Gainor

9011

Response to checkpoint inhibition in lung cancer with molecular driver alterations.

Amanda Tufman

e21071

Responses and durability in NSCLC treated with pegilodecakin and anti-PD-1.

Edward B. Garon

9018

Results from a second-line (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-β and PD-L1.

Luis G. Paz-Ares

9017

Retrospective analysis of clinical outcome of EGFR mutated patients in a county hospital.

Srijana Rai

e21208

Rh-endostatin combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in NSCLC: A retrospective comparison with standard chemotherapy.

Shengyu Zhou

e21198

Risk of not receiving 2nd line therapy is high in EGFR mt+ pts: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ pts.

Julia Roeper

e21220

Role of immune checkpoint inhibitor, tumor vaccine and cellular immunotherapy in advanced non-small-cell lung cancer.

Yunfang Yu

e21056

Safety analysis of an open label, randomized phase 2 study of osimertinib alone versus osimertinib plus carboplatin-pemetrexed for patients with non–small cell lung cancer (NSCLC) that progressed during prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and which harbors a T790M mutation of EGFR.

Morihito Okada

e21073

Safety and activity of durvalumab + tremelimumab in immunotherapy (IMT)-pretreated advanced NSCLC patients.

Edward B. Garon

9041

Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC).

Dong-Wan Kim

9009

Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC.

Zofia Piotrowska

e21231

Sarcopenia and toxicity of the anti-PD1 inhibitors in real-life lung cancer patients: Results from the French Nationwide SCAN study.

Marie-Pierre Revel

e21066

Second-line therapy to improve overall survival in primary refractory non small-cell lung cancer (NSCLC) patients.

Sacha Rothschild

e21069

Sequencing of ramucirumab (ram) and immune checkpoint inhibitors (ICIs) in platinum (Pt)-treated real-world patients (pts) with advanced non-small cell lung cancer (aNSCLC).

Jeffrey Melson Clarke

e21209

Sequential monitoring of CAMLs in circulation as predictive of progression in lung cancer patients undergoing definitive radiotherapy.

Daniel Adams

e21062

Small cell transformation as a mechanism of resistance to immunotherapy of non-small cell lung cancer.

Jair Bar

e21230

Subgroup analysis of elderly patients (pts) in ALTER0303: Anlotinib hydrochloride as 3rd-line and further line treatment in refractory advanced NSCLC pts from a randomized, double-blind, placebo-controlled phase III ALTER0303 trial.

Jianhua Shi

e21181

Subgroup analysis of histology in ALTER0303: Anlotinib hydrochloride as 3rd line and further line treatment in refractory advanced NSCLC patients (pts).

Ying Cheng

9080

Survival disparities among African American (AA) patients (pts) with EGFR-mutated non-small cell lung cancer (NSCLC).

Haiying Cheng

9054

Survival of crizotinib continuation plus brain radiotherapy among ALK positive non-small cell lung cancer (NSCLC) patients with brain metastases during crizotinib treatment.

Guangjian Yang

e21142

Survival, value and relative value of the immune check point inhibitors vs. docetaxel in 2nd-line treatment of non-small-cell lung cancer.

Helmy M. Guirgis

e21098

Targeting NFE2L2 mutations in advanced squamous cell lung cancers with the TORC1/2 inhibitor TAK228.

Paul K. Paik

9098

Technical and clinical validation of somatic CNV detection from circulating tumor DNA.

Kaican Cai

e21055

Tepotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14-skipping mutations: Phase II trial.

Enriqueta Felip

9016

The correlation between Crizotinib efficacy and molecular heterogeneity by next-generation sequencing in non-small cell lung cancer.

Tangfeng Lv

e21167

The effect and safety of an immune checkpoint inhibitor rechallenge in non-small cell lung cancer.

Hiromi Watanabe

e21147

The effect of thoracic radiation on overall survival and their association with systemic immune therapy in stage IV NSCLC: Findings from the National Cancer Database.

Feng-Ming Spring Kong

9103

The efficacy and safety of PD-1 inhibitors in combination with or without chemotherapy and/or bevacizumab as second line treatment or beyond in non-small cell lung cancer: Preliminary data from a real-world setting.

Fan Zhang

e21129

The impact of different brain imaging strategies for initial staging and post-treatment surveillance in patients with EGFR-mutant lung adenocarcinomas.

Chia-I Shen

e21145

The importance of body composition and physical function on overall survival (OS) in non-small cell lung cancer (NSCLC) patients receiving platinum based chemotherapy (PBCT).

Emily Kinsey

e21088

The negative association between Charlson Comorbidity Index and TNM stage at diagnosis in non-small cell lung cancer.

James X Zhang

e21118

The prevalence of TP53 mutation and primary resistance mechanisms in short-term responders to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.

Yun Fan

e21237

The role of FDG-PET during osimertinib treatment to predict the responsiveness of tumor early in patients with stage IV non-small cell lung cancer: A pilot study.

Shinkyo Yoon

e21150

The use of chemotherapy in elderly patients with metastatic non-small cell lung cancer: A National Cancer Database analysis.

Lara Ann Kujtan

e21235

Therapeutic and prognostic impact of genetic alterations identified in nationwide genome screening for squamous cell lung cancer (LC-SCRUM-Japan).

Tomohiro Sakamoto

9074

Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: A single institution, retrospective cohort study.

Irena Tan

e21222

Time to treatment discontinuation (TTD) as a pragmatic endpoint in metastatic non-small cell lung cancer (mNSCLC): A pooled analysis of 8 trials.

Yutao Gong

9064

To censor or not to censor? Impact on real-world treatment duration.

Sarika Ogale

e21111

Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from phase 1 dose escalation and NSCLC Expansion Cohort.

Victor Moreno Garcia

e21057

Treatment decision making after introduction of PD-L1 reflex testing in NSCLC up front.

Karin Holmskov Hansen

e21149

Trial in progress: Multicenter observational study to evaluate the relationship between gut bacterial flora and their therapeutic or adverse effects in advanced non-small cell lung cancer patients treated with nivolumab.

Takashi Yokoi

TPS9114

Tumor mutation burden and efficacy of targeted therapy in patients with EGFR mutant lung cancers.

Michael David Offin

9042

Tyrosine kinase inhibitor (TKI) cessation in advanced non-small-cell lung cancer (aNSCLC) for improved detection of EGFR-mutated (EGFRm) circulating tumor DNA (ctDNA).

Samer Tabchi

e21064

Understanding patient and physician perceptions of cell and gene therapy in oncology: A pilot study using qualitative interviews and social media data.

Ramesh Arjunji

e21194

Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC.

D. Ross Camidge

9043

Using the GeneReader NGS system and QIAact lung all-in-one assay to detect complex mutations and fusions.

Simon Hughes

e21193

Value based healthcare and patient reported outcome measures (PROMS) in clinical practice: pilot trial in lung cancer.

Ingel Demedts

e21107

YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results.

Byoung Chul Cho

9033